INTRODUCTION {#sec1-1}
============

Current approaches for the treatment of fungal corneal infections trust on topical administration of antifungal agents.\[[@ref1][@ref2][@ref3][@ref4]\] Voriconazole (triazole antifungal) is a second-generation synthetic derivative of fluconazole.\[[@ref5]\] Voriconazole acts as an enzyme inhibitor, blocking the synthesis of ergosterol, a constituent of fungal membranes, and thus the growth of the microorganism. It has a broad spectrum of activity with lower minimum inhibitory concentrations (MIC), in addition to a high systemic intraocular penetration profile.\[[@ref6][@ref7]\] Voriconazole is effective against a wide spectrum of keratitis-causative fungi.\[[@ref7][@ref8][@ref9]\] Voriconazole is commercially available in oral and intravenous forms.\[[@ref10]\] Oral voriconazole is highly bioavailable (96%) and has many side-effects with significant drug interactions.\[[@ref11]\] Treatment of fungal keratitis with systemic voriconazole is costly.\[[@ref12]\] For this reason, an efficient and economical approach of voriconazole delivery in the treatment of fungal keratitis is very much desirable. Topical voriconazole was reported to penetrate well through the cornea and achieve noticeable levels in rabbits\[[@ref13]\] and in horses.\[[@ref14]\] Eye drops are the most cost-effective and competent system for delivering a medicament into the eye.\[[@ref15]\] Topical delivery of drugs to the ocular tissues is affected by a complex interplay of biological, physiochemical and formulation factors. Designing an ophthalmic delivery system is one of the most challenging tasks for the researchers.\[[@ref16]\] Formulators usually have to design a dosage form, which provides a balance between the corneal penetration, ocular irritation and formulation stability. Manipulation of formulation parameters to enhance the corneal penetration is one of the approaches of increasing ocular availability.\[[@ref17]\[[@ref18]\] Animal Ethics Committees are discouraging experiments with rabbit cornea. Therefore, it appears logical to search for alternate mammalian corneas, especially from those animals that are slaughtered every day for meat (e.g., goat and sheep). In addition, such a study would also help in the development of veterinary ophthalmic formulation of the drug for the cattle population in the Indian subcontinent. The present investigation was aimed to develop voriconazole eye drops and to evaluate the effect of pH, concentration of drug, viscosity modifier, preservative and stabilizers on the corneal permeation of voriconazole through freshly isolated goat and sheep cornea.

MATERIALS AND METHODS {#sec1-2}
=====================

Materials {#sec2-1}
---------

Voriconazole (purity 99.9%) was obtained from Matrix laboratories, Hyderabad and beta-cyclodextrin (β-CD) was obtained from Dr. Reddy\'s Labs, Hyderabad as gift. Freeze-dried microbial cultures of *Candida albicans* (MTCC NO. 3017), *Candida glabrata* (MTCC NO. 3019), *Aspergillus flavus* (MTCC NO. 3306) and *Fusarium solani* (MTCC NO. 3763) were purchased from Institute of Microbial Technology, Chandigarh, India. All other chemicals were of analytical grade. Fresh eyeballs of goat and sheep were obtained from a local butchers shop (Baripada, Odisha, India) within 1 h of slaughtering of animals. The method of dissection of the cornea and the apparatus used in the permeation studies was the same as published elsewhere.\[[@ref19]\]

Determination of Aqueous Solubility of Voriconazole {#sec2-2}
---------------------------------------------------

An excess amount of voriconazole was added to distilled water to prepare a saturated solution at room temperature and was shaken in a reciprocating shaker at 200 rpm (Satyam equipments, New Delhi) for 48 h at 25°C ± 0.5°C.\[[@ref20]\] The solution was filtered, diluted and analyzed for voriconazole content by measuring absorbance in a spectrophotometer (ultraviolet-1700, Shimadzu) at 256 nm. The solubility was determined in triplicate.

Preparation of Test Solutions {#sec2-3}
-----------------------------

### Voriconazole ophthalmic solutions (0.05% w/v) of different pH {#sec3-1}

Voriconazole (0.05 g) was dissolved in sufficient distilled water; sodium chloride (0.895 g/100 ml) was added to make the final solution isotonic; the pH of the solution was adjusted to 4.0, 5.0, 6.0, 7.0 or 8.0 using 0.1N HCl or 0.1N NaOH and final volume were made up to 100 ml with distilled water to have solutions of different pH.

### Voriconazole ophthalmic solutions (0.05% w/v, pH 7.2) containing preservatives {#sec3-2}

Voriconazole (0.05 g) was dissolved in sufficient distilled water; sodium chloride (0.895 g/100 ml) was added to make the final solution isotonic; and pH of the solution was adjusted to 7.2. To this solution benzalkonium chloride (BKC 0.01% w/v), thiomersal (THM, 0.005% w/v), phenyl mercuric acetate (PMA, 0.002% w/v), phenyl mercuric nitrate (PMN, 0.002% w/v), disodium edetate (ethylenediaminetetraacetic acid) (EDTA, 0.01% w/v), sodium metabisulfite (SMS, 0.1% w/v), combination of BKC (0.01% w/v) and EDTA (0.01% w/v) or combination of SMS (0.1% w/v) and EDTA (0.01% w/v) was added. The final volume of each solution was made up to 100 ml with distilled water.

### Voriconazole ophthalmic solutions (pH 7.2) of increasing concentration {#sec3-3}

Required amount of physical mixture of voriconazole and β-CD in a ratio of 1:2 was dissolved in sufficient distilled water; sodium chloride (0.895 g/100 ml) was added to make the final solution isotonic; and pH of the solution was adjusted to 7.2 using 0.1N HCl or 0.1N NaOH and final volume were made up to 100 ml with distilled water, to have solutions of 0.05, 0.1, 0.15 and 0.2% (w/v) concentrations.

### Ophthalmic solutions (0.2% w/v, pH 7.2) with β-CD containing viscosity modifier {#sec3-4}

Required amount of physical mixture of voriconazole and β-CD in a ratio of 1:2 was dissolved in sufficient distilled water; sodium chloride (0.895 g/100 ml) was added to make the final solution isotonic; and pH of the solution was adjusted to 7.2 using 0.1N HCl and 0.1N NaOH. To this solution methylcellulose (MC) (0.25%, w/v), hydroxyl propyl methylcellulose (HPMC) (0.25%, w/v), polyvinyl alcohol (PVA) (1.4%, w/v) or polyvinylpyrrolidone (PVP) (1%, w/v) was added and the final volume of each solution was made up to 100 ml with distilled water.

Determination of Partition Coefficient {#sec2-4}
--------------------------------------

Equal volumes of voriconazole ophthalmic solution (0.05% w/v, pH 7.2) with or without additive (control) and n-octanol were shaken at room temperature in a reciprocating shaker at 200 rpm (Satyam equipments, New Delhi) for 2 h.\[[@ref21]\] Voriconazole content in the aqueous phase of each experiment was analyzed and partition coefficients were calculated. The experiments were done with triplicate sample of each formulation. The result was expressed as mean ± standard deviation.

Measurement of Surface Tension and Viscosity {#sec2-5}
--------------------------------------------

The surface tension of each ophthalmic solution (0.05% w/v) was measured by using a stalagmometer and the viscosity of each ophthalmic solution (0.05% and 0.2% w/v) was measured using an Ostwald viscometer.

Permeation Experiment {#sec2-6}
---------------------

Freshly excised cornea was mounted between clamped donor and receptor compartments of an all glass modified Franz diffusion cell in such a way that its epithelial surface faced the donor compartment. The corneal area available for diffusion was 0.64 cm^2^. The receptor compartment was filled with 11.4 ml of freshly prepared bicarbonate ringer solution (pH 7.4). The donor sample (1 ml of drug solution) was placed on the cornea. The opening of the donor compartment was sealed with a cover slip and the receptor compartment was maintained at 37°C with constant stirring, using a Teflon-coated magnetic stir bead. Permeation study was continued for 120 min. The sample was withdrawn from the receptor compartment and analyzed for voriconazole content using a spectrophotometer at 256 nm. Results were expressed as an amount permeated and percentage permeation. The permeation (%) or *in vitro* ocular availability was calculated as follows;
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At the end of the experiment, the scleral tissue was removed from cornea; its epithelial surface was wiped with filter paper and weighed. The cornea was then soaked in 1 ml methanol, dried overnight at 90°C, and reweighed. From the difference in weight, corneal hydration (%) was calculated.

Antifungal Study {#sec2-7}
----------------

The antifungal activities of all formulations were evaluated against *C. albicans*, *C. glabrata*, *A. flavus* and *F. solani*. The fungal strains were maintained on agar slants (malt yeast agar media for *C. albicans* and *C. glabrata*, malt extract agar media for *A. flavus* and potato sucrose agar media for *F. solani*). Antifungal activity was evaluated by paper disc diffusion method (IP 1985). The medium used for the antifungal activities was same as the maintenance medium of respective fungi. The slant of the microorganism was washed with sterile saline and the cell suspension was further diluted with sterile saline. The cell suspension (0.1 ml) was used to inoculate 100 ml of molten media (sterile). This inoculated medium was poured in 20 ml quantities into 9 cm petridishes (borosil) and the medium was allowed to solidify. Sterile paper discs of 4 mm diameter (made from Whatman No.1 filter paper) were soaked in the eye drop formulation (sterile) and each disc in triplicate was placed in the inoculated media contained in the petridish. Each petridish was incubated at 25°C. As per the specification supplied by MTCC, Chandigarh, the incubation period was 2 days for *C. albicans* and *C. glabrata* and 5 days for *A. flavus* and F. solani. After the specified period of incubation, the clear zone of inhibition (ZOI) in each petridish was measured in cm.

RESULTS AND DISCUSSION {#sec1-3}
======================

[Table 1](#T1){ref-type="table"} shows the partition coefficient, viscosity and surface tension of voriconazole drops containing different preservative. Effect of pH on corneal permeation of voriconazole through excised goat corneas is shown in [Table 2](#T2){ref-type="table"}. Increase the pH of voriconazole formulation from pH 4.0 to 8.0 resulted in significant (*P* \< 0.05) increase in permeation of voriconazole, indicating a pH-dependent transport of voriconazole. Corneal permeation depends mainly on the drug\'s molecular size,\[[@ref22][@ref23]\] on its oil/water partition coefficient\[[@ref22][@ref24][@ref25][@ref26]\] and its degree of ionization.\[[@ref27][@ref28]\] In addition, unionized form of ionizable acidic or basic compound penetrates corneal epithelium mainly due to its higher lipid solubility.\[[@ref29][@ref30]\] Fraction of ionized and un-ionized molecules affect the rate and extent of transcorneal transport, which in turn depends on the pKa of the drug and the pH of the formulation.\[[@ref31]\] Voriconazole, being a basic drug, would be in unionized form as the pH of the formulation is shifted toward neutrality resulting in increased permeation. Increased permeation of voriconazole at physiological pH of tears (i.e., pH 7.2) might be because cornea contains both positively and negatively charged groups whose magnitude and polarity depend on the degree of protonation. The average pH of tears is 7.2 and eyes can tolerate pH of 6.5-8.0 without much discomfort.\[[@ref17]\] The cornea carries a net negative charge at pH above the isoelectric point (pI = 3.2) and is selectively permeable to cations.\[[@ref32]\] Permeation of moxifloxacin\[[@ref21]\] across the excised goat, sheep, buffalo corneas and the permeation of levofloxacin across the excised rabbit cornea has also been reported to be pH-dependent.\[[@ref33]\]

###### 

Physicochemical properties of voriconazole aqueous drops
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###### 

Effect of pH on permeation of voriconazole from 0.05% aqueous solution through excised goat cornea
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[Table 3](#T3){ref-type="table"} shows the effect of concentration of voriconazole in ophthalmic solution on corneal permeability. Voriconazole is a lipophilic compound with low aqueous solubility. The aqueous solubility of voriconazole could be enhanced by physical mixing of voriconazole and β-CD in a weight ratio of 1:1 and 1:2. Physical mixture of voriconazole and β-CD (1:2) was selected to prepare 0.2% (w/v) solution at pH 7.2 due to its higher solubility. Increase in drug concentration in the formulation resulted in significant (*P* \< 0.05) increase in permeation of voriconazole after 120 min, but decreased the percentage permeation or *in vitro* ocular availability. The cornea has three layers: The epithelium, the stroma and the endothelium. Only the amount of drug needed to saturate the epithelium would be able to partition through the stroma and endothelium to the receptor. As a result, an increase in concentration would have a negative effect on the *in vitro* ocular availability of the drug. Similar findings of reduced *in vitro* ocular availability with an increase in drug concentration have been reported for ibuprofen, flurbiprofen\[[@ref34]\] and moxifloxacin.\[[@ref21]\]

###### 

Effect of concentration on permeation of voriconazole from aqueous solution through excised goat cornea
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Inclusion of β-CD enhanced the corneal permeation of voriconazole. CD is reported to enhance drug penetration into the eye by carrying the lipopilic drug molecules through the aqueous mucin layer and thus increasing drug availability at the lipophilic eye surface without disruption of ophthalmic barrier like BKC, a conventional penetration enhancer.\[[@ref35]\] CDs have earlier been reported to enhance,\[[@ref36]\] diminish\[[@ref37]\] and have no effects\[[@ref38]\] on the corneal transport of drugs. The result of corneal hydration was more than the normal range of 75% to 80% indicating slight damage to the corneas.\[[@ref39]\] Since the corneal hydration is below 83%, the damage appears to be reversible.\[[@ref40]\]

The results of corneal permeation of voriconazole from ophthalmic solution (0.05% w/v, pH 7.2) preserved with different preservatives are shown in [Table 4](#T4){ref-type="table"}. Formulation with EDTA (0.01% w/v) showed significantly (*P* \< 0.05) higher permeation than did the control formulation containing no preservatives. EDTA has been reported to increase corneal absorption of various drugs through intact corneas.\[[@ref32][@ref41][@ref42]\] EDTA, a known calcium-chelating agent, has been shown to act on cell junctions by interfering with calcium ions and altering intercellular integrity. EDTA also disrupts the plasma membrane and thereby increases intercellular permeability.\[[@ref43]\] In addition, the anionic EDTA interacts with cationic voriconazole to form more lipid-soluble ion pair, which may increase the permeation of drug through the cornea. Formulation with BKC, the combination of BKC and EDTA, combination of SMS and EDTA resulted in significant (*P* \< 0.05) increase in permeation of voriconazole than control formulation. Formulation with PMN produced significantly (*P* \< 0.05) lower permeation of voriconazole than did the control formulation. BKC, a cationic surfactant has been reported to increase the corneal permeation of drugs by emulsification and disruption of the corneal epithelium.\[[@ref44]\] Combination of BKC and EDTA has been observed to increase the corneal permeation of fluoroquinolones like moxifloxacin\[[@ref21]\] and gatifloxacin.\[[@ref45]\] The addition of BKC in the formulation reduced surface tension of voriconazole drop from 67.59 to 37.90 dynes/cm. Partitioning experiment indicated partition coefficient of voriconazole in n-octanol/voriconazole drop with EDTA or BKC was higher than the control formulation containing no preservative. Thus, EDTA or BKC increased the partitioning of voriconazole in the lipid phase. The result of corneal hydration showed higher than the normal range in the formulation with BKC (80.67%) and with the combination of BKC and EDTA (81.59%) indicating slight corneal damage.

###### 

Effect of preservative on permeation of voriconazole from 0.05% (w/v) aqueous solution (pH 7.2) through excised goat and sheep cornea
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The effect of viscosity modifier on the transcorneal permeation of the drug evaluated using excised goat corneas are shown in [Table 5](#T5){ref-type="table"}. Viscosity modifiers are used in eye drops to prolong the precorneal residence of drugs. Formulation with MC and with PVA resulted in significant (*P* \< 0.05) decrease in permeation of voriconazole than control formulation containing no viscosity modifier.

###### 

Effect of viscolizing agents on permeation of voriconazole from 0.2% (w/v) aqueous solution (pH 7.2) through excised goat cornea
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The antifungal study of the eye drops against *C. albicans*, *C. glabrata*, *A. flavus* and *F. solani* was evaluated. The diameters of clear ZOI are shown in Figures [1](#F1){ref-type="fig"}-[3](#F3){ref-type="fig"}. Most of the formulations showed higher ZOI against *C. albicans*.

![Comparison of the diameter of zone of inhibition (cm) of voriconazole drops (0.05% w/v) against *Candida albicans*, *Candida glabrata*, *Aspergillus flavus* and *Fusarium solani*](JAPTR-4-210-g007){#F1}

![Comparison of the diameter of zone of inhibition (cm) of voriconazole drops (0.2% w/v) against *Candida albicans*, *Candida glabrata*, *Aspergillus flavus* and *Fusarium solani*](JAPTR-4-210-g008){#F2}

![Photographs of zone of inhibition of voriconazole drops (0.05% w/v) against *Candida albicans*, *Candida glabrata*, *Aspergillus flavus* and *Fusarium solani*](JAPTR-4-210-g009){#F3}

CONCLUSIONS {#sec1-4}
===========

Based on the present study it can be concluded that voriconazole 0.05% (w/v) ophthalmic solution (pH 7.2) containing EDTA (0.01% w/v), BKC (0.01% w/v) and a combination of BKC and EDTA (each 0.01% w/v) provides significantly (*P* \< 0.05) higher permeation of voriconazole than did the control formulation. Corneal transport of voriconazole is both pH and concentration dependent. Most of the formulations showed higher ZOI against *C. albicans*.

Authors are thankful to Matrix laboratories (Hyderabad, India) for a gift sample of voriconazole.

**Source of Support:** Nil

**Conflict of Interest:** Nil.
